Trials / Terminated
TerminatedNCT00179751
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma. Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles until documented disease progression occurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 | |
| DRUG | gemcitabine |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-08-01
- First posted
- 2005-09-16
- Last updated
- 2005-11-07
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00179751. Inclusion in this directory is not an endorsement.